sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.
|
saquinavir
|
VIRACEPT
|
MECHANISM
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s18
|
DDI-DrugBank.d340.s18.p6
|
- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
|
Indocin
|
Aleve
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s2
|
DDI-DrugBank.d521.s2.p271
|
No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa/dopa-decarboxylase inhibitor.
|
tricyclic antidepressant
|
entacapone
|
NONE
|
Entacapone_ddi.xml
|
DDI-DrugBank.d455.s11
|
DDI-DrugBank.d455.s11.p1
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
cholestyramine
|
contraceptives
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p178
|
Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
|
diclofenac
|
digoxin
|
EFFECT
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s5
|
DDI-DrugBank.d249.s5.p2
|
Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.
|
aliskiren
|
furosemide
|
MECHANISM
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s9
|
DDI-DrugBank.d533.s9.p3
|
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.
|
Imidazoles
|
ketoconazole
|
NONE
|
Amphotericin B_ddi.xml
|
DDI-DrugBank.d318.s8
|
DDI-DrugBank.d318.s8.p0
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
levothyroxine sodium
|
estrogen-containing compounds
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p5
|
Nevertheless, caution is indicated in the co-administration of T.A. with any of the SSRIs and also in switching from one class to the other.
|
T.A.
|
SSRIs
|
ADVISE
|
Desipramine_ddi.xml
|
DDI-DrugBank.d386.s12
|
DDI-DrugBank.d386.s12.p0
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
quinolone
|
aluminum
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p2
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
Chlorotrianisene
|
corticosteroids
|
INT
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p5
|
In vitro data suggest that itraconazole, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.
|
itraconazole
|
astemizole
|
MECHANISM
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s5
|
DDI-DrugBank.d165.s5.p1
|
Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.
|
Trileptal
|
hormonal contraceptives
|
EFFECT
|
Oxcarbazepine_ddi.xml
|
DDI-DrugBank.d307.s43
|
DDI-DrugBank.d307.s43.p0
|
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
|
fluoxetine
|
CMI
|
MECHANISM
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s6
|
DDI-DrugBank.d238.s6.p17
|
Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.
|
rifampicin
|
phenytoin
|
NONE
|
Exemestane_ddi.xml
|
DDI-DrugBank.d435.s2
|
DDI-DrugBank.d435.s2.p0
|
Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.
|
Quinolones
|
anticoagulants
|
EFFECT
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s5
|
DDI-DrugBank.d217.s5.p1
|
Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant.
|
methaqualone
|
anticoagulant agents
|
INT
|
1109248.xml
|
DDI-MedLine.d106.s8
|
DDI-MedLine.d106.s8.p2
|
Warfarin-Vitamin K can antagonize the effect of warfarin
|
Warfarin
|
Vitamin K
|
NONE
|
Menadione_ddi.xml
|
DDI-DrugBank.d139.s8
|
DDI-DrugBank.d139.s8.p0
|
Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;
|
Nevirapine
|
combination hormonal contraceptives
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s27
|
DDI-DrugBank.d485.s27.p5
|
If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
|
sumatriptan
|
citalopram
|
ADVISE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s17
|
DDI-DrugBank.d568.s17.p5
|
Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.
|
rifampin
|
efavirenz
|
MECHANISM
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s5
|
DDI-DrugBank.d531.s5.p4
|
Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.
|
Buforin II
|
minocycline
|
EFFECT
|
11152438.xml
|
DDI-MedLine.d47.s4
|
DDI-MedLine.d47.s4.p1
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
disopyramide
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p44
|
Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects
|
Accutane
|
vitamin A
|
EFFECT
|
Isotretinoin_ddi.xml
|
DDI-DrugBank.d163.s0
|
DDI-DrugBank.d163.s0.p4
|
FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.
|
FLEXERIL
|
alcohol
|
EFFECT
|
Cyclobenzaprine_ddi.xml
|
DDI-DrugBank.d150.s1
|
DDI-DrugBank.d150.s1.p0
|
Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.
|
Vardenafil
|
terazosin
|
EFFECT
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s28
|
DDI-DrugBank.d198.s28.p2
|
Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.
|
Fluvoxamine
|
alosetron
|
MECHANISM
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s3
|
DDI-DrugBank.d364.s3.p0
|
Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.
|
Felbamate
|
gestodene
|
MECHANISM
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s38
|
DDI-DrugBank.d434.s38.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Crixivan
|
rifadin
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p831
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
fenoprofen
|
trimethoprim
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p921
|
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylureas
|
coumarins
|
EFFECT
|
Glibenclamide_ddi.xml
|
DDI-DrugBank.d178.s0
|
DDI-DrugBank.d178.s0.p5
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
phenyramidol
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p37
|
Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
|
quinolones
|
magnesium
|
MECHANISM
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s1
|
DDI-DrugBank.d78.s1.p2
|
Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
|
Coumarin Anticoagulants
|
capecitabine
|
NONE
|
Capecitabine_ddi.xml
|
DDI-DrugBank.d88.s3
|
DDI-DrugBank.d88.s3.p0
|
Beta-adrenergic blocking agents: Coadministration of beta-adrenergic blocking agents did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.
|
Beta-adrenergic blocking agents
|
beta-adrenergic blocking agents
|
NONE
|
Ibutilide_ddi.xml
|
DDI-DrugBank.d68.s5
|
DDI-DrugBank.d68.s5.p0
|
On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.
|
amiodarone
|
digitalis
|
ADVISE
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s24
|
DDI-DrugBank.d143.s24.p0
|
Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.
|
FOSCAVIR
|
pentamidine
|
ADVISE
|
Foscarnet_ddi.xml
|
DDI-DrugBank.d511.s4
|
DDI-DrugBank.d511.s4.p6
|
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.
|
piroxicam
|
phenytoin
|
NONE
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s4
|
DDI-DrugBank.d3.s4.p23
|
Potassium-depleting diuretics are a major contributing factor to digitalis toxicity.
|
Potassium-depleting diuretics
|
digitalis
|
EFFECT
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s0
|
DDI-DrugBank.d450.s0.p0
|
Cholestyramine, an anionic-binding resin, has a considerable effect in lowering the rate and extent of fluvastatin bioavailability.
|
Cholestyramine
|
fluvastatin
|
MECHANISM
|
19489169.xml
|
DDI-MedLine.d119.s15
|
DDI-MedLine.d119.s15.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
risperidone
|
valproate
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p995
|
Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.
|
carbamazepine
|
Clozapine
|
MECHANISM
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s18
|
DDI-DrugBank.d480.s18.p5
|
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
|
antacids
|
fosinopril
|
MECHANISM
|
Fosinopril_ddi.xml
|
DDI-DrugBank.d176.s9
|
DDI-DrugBank.d176.s9.p44
|
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.
|
quinidine
|
theophylline
|
NONE
|
11206047.xml
|
DDI-MedLine.d111.s5
|
DDI-MedLine.d111.s5.p77
|
Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin.
|
L-arginine
|
cyclosporin
|
EFFECT
|
L-Arginine_ddi.xml
|
DDI-DrugBank.d95.s0
|
DDI-DrugBank.d95.s0.p2
|
If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
|
desipramine hydrochloride
|
sedative
|
EFFECT
|
Desipramine_ddi.xml
|
DDI-DrugBank.d386.s23
|
DDI-DrugBank.d386.s23.p2
|
Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
|
benzodiazepine class
|
monoamine oxidase inhibitors
|
EFFECT
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s7
|
DDI-DrugBank.d333.s7.p8
|
Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.
|
felbamate
|
phenytoin
|
MECHANISM
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s14
|
DDI-DrugBank.d434.s14.p0
|
Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively. A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.
|
fluconazole
|
lovastatin
|
NONE
|
Mefenamic acid_ddi.xml
|
DDI-DrugBank.d400.s14
|
DDI-DrugBank.d400.s14.p25
|
In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.
|
AED
|
oxcarbazepine
|
MECHANISM
|
Oxcarbazepine_ddi.xml
|
DDI-DrugBank.d307.s1
|
DDI-DrugBank.d307.s1.p0
|
A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.
|
lopinavir
|
nevirapine
|
ADVISE
|
Nevirapine_ddi.xml
|
DDI-DrugBank.d270.s39
|
DDI-DrugBank.d270.s39.p1
|
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
|
FLOLAN
|
digoxin
|
NONE
|
Epoprostenol_ddi.xml
|
DDI-DrugBank.d241.s3
|
DDI-DrugBank.d241.s3.p9
|
Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
|
phenytoin
|
valproic acid
|
NONE
|
Ethosuximide_ddi.xml
|
DDI-DrugBank.d205.s0
|
DDI-DrugBank.d205.s0.p18
|
Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).
|
carbonic anhydrase inhibitors
|
salicylate
|
NONE
|
Dorzolamide_ddi.xml
|
DDI-DrugBank.d34.s0
|
DDI-DrugBank.d34.s0.p2
|
In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.
|
ciprofloxacin
|
didanosine
|
MECHANISM
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s11
|
DDI-DrugBank.d43.s11.p0
|
As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin
|
losartan
|
indomethacin
|
EFFECT
|
Losartan_ddi.xml
|
DDI-DrugBank.d30.s9
|
DDI-DrugBank.d30.s9.p4
|
Concomitant administration of alosetron and fluvoxamine is contraindicated.
|
alosetron
|
fluvoxamine
|
ADVISE
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s4
|
DDI-DrugBank.d364.s4.p0
|
Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.
|
Fluconazole
|
celecoxib
|
NONE
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s16
|
DDI-DrugBank.d172.s16.p1
|
Antacid: The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.
|
magnesium hydroxide
|
Maalox
|
NONE
|
Capecitabine_ddi.xml
|
DDI-DrugBank.d88.s0
|
DDI-DrugBank.d88.s0.p10
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
antidepressants
|
imipramine
|
NONE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p17
|
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
|
ciprofloxacin
|
diclofenac
|
NONE
|
Chlorpheniramine_ddi.xml
|
DDI-DrugBank.d235.s4
|
DDI-DrugBank.d235.s4.p14
|
Studies in humans show that the absorption of chlorothiazide as reflected in urinary excretion is markedly decreased even when administered one hour before colestipol hydrochloride.
|
chlorothiazide
|
colestipol hydrochloride
|
MECHANISM
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s10
|
DDI-DrugBank.d345.s10.p0
|
Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
|
amlodipine
|
aliskiren
|
NONE
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s1
|
DDI-DrugBank.d533.s1.p65
|
Nitrofurantoin interferes with the therapeutic action of nalidixic acid.
|
Nitrofurantoin
|
nalidixic acid
|
EFFECT
|
Nalidixic Acid_ddi.xml
|
DDI-DrugBank.d427.s7
|
DDI-DrugBank.d427.s7.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
vitamin C
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p43
|
Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.
|
Rifampin
|
ethinyl estradiol
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s36
|
DDI-DrugBank.d485.s36.p4
|
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
|
glimepiride
|
bismuth subsalicylate
|
ADVISE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s1
|
DDI-DrugBank.d521.s1.p10
|
It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
|
TCA
|
TCA
|
NONE
|
Imipramine_ddi.xml
|
DDI-DrugBank.d77.s21
|
DDI-DrugBank.d77.s21.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
buspirone
|
quetiapine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p244
|
Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats.
|
Loperamide
|
dmPGE2
|
EFFECT
|
7625885.xml
|
DDI-MedLine.d128.s13
|
DDI-MedLine.d128.s13.p1
|
Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
|
enalapril
|
antihypertensive agents
|
EFFECT
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s3
|
DDI-DrugBank.d107.s3.p1
|
Iron salts may reduce the bioavailability of carbidopa and levodopa.
|
Iron
|
carbidopa
|
MECHANISM
|
Carbidopa_ddi.xml
|
DDI-DrugBank.d47.s5
|
DDI-DrugBank.d47.s5.p0
|
Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
|
SSRIs
|
5-HT1 agonists
|
EFFECT
|
Frovatriptan_ddi.xml
|
DDI-DrugBank.d426.s3
|
DDI-DrugBank.d426.s3.p10
|
The fraction of STADOL NS absorbed is unaffected by the concomitant administration of a nasal vasoconstrictor (oxymetazoline), but the rate of absorption is decreased.
|
nasal vasoconstrictor
|
oxymetazoline
|
NONE
|
Butorphanol_ddi.xml
|
DDI-DrugBank.d246.s13
|
DDI-DrugBank.d246.s13.p2
|
Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other s metabolism.
|
Phenothiazine-related compounds
|
beta-adrenergic blocking agents
|
MECHANISM
|
Levobunolol_ddi.xml
|
DDI-DrugBank.d252.s5
|
DDI-DrugBank.d252.s5.p0
|
The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.
|
ciprofloxacin
|
didanosine
|
MECHANISM
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s10
|
DDI-DrugBank.d43.s10.p2
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
tetracycline
|
atorvastatin
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p221
|
Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.
|
cyclosporine
|
TRICOR
|
EFFECT
|
Fenofibrate_ddi.xml
|
DDI-DrugBank.d283.s5
|
DDI-DrugBank.d283.s5.p4
|
In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.
|
cerivastatin sodium
|
cholestyramine
|
MECHANISM
|
Cerivastatin_ddi.xml
|
DDI-DrugBank.d141.s4
|
DDI-DrugBank.d141.s4.p0
|
Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
|
ethosuximide
|
antiepileptic drugs
|
INT
|
Ethosuximide_ddi.xml
|
DDI-DrugBank.d205.s0
|
DDI-DrugBank.d205.s0.p6
|
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist.
|
theophylline
|
CGS 21680
|
EFFECT
|
7746025.xml
|
DDI-MedLine.d51.s3
|
DDI-MedLine.d51.s3.p0
|
These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.
|
methotrexate
|
ELSPAR
|
ADVISE
|
Asparaginase_ddi.xml
|
DDI-DrugBank.d21.s1
|
DDI-DrugBank.d21.s1.p0
|
Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
|
ketoconazole
|
digoxin
|
NONE
|
Esomeprazole_ddi.xml
|
DDI-DrugBank.d29.s12
|
DDI-DrugBank.d29.s12.p4
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
contraceptives
|
rifampin
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p68
|
Likewise, gabapentin pharmacokinetics were unaltered by carbamazepine administration.
|
gabapentin
|
carbamazepine
|
NONE
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s10
|
DDI-DrugBank.d438.s10.p0
|
d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
|
d-amphetamine
|
tricyclics
|
MECHANISM
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s4
|
DDI-DrugBank.d158.s4.p2
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
pimozide
|
alprazolam
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p118
|
Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
|
ALPHAGAN P
|
anesthetics
|
ADVISE
|
Brimonidine_ddi.xml
|
DDI-DrugBank.d138.s0
|
DDI-DrugBank.d138.s0.p5
|
Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
nonsteroidal anti-inflammatory agents
|
antidiabetic drugs
|
EFFECT
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s14
|
DDI-DrugBank.d460.s14.p5
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
DURAGESIC
|
sedatives
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p15
|
Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
|
phenytoin
|
phenobarbital
|
NONE
|
Calcitriol_ddi.xml
|
DDI-DrugBank.d384.s2
|
DDI-DrugBank.d384.s2.p9
|
In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.
|
serotonin reuptake inhibitor drug
|
monoamine oxidase inhibitors
|
EFFECT
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s1
|
DDI-DrugBank.d76.s1.p0
|
Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.
|
acitretin
|
glibenclamide
|
EFFECT
|
Acitretin_ddi.xml
|
DDI-DrugBank.d353.s1
|
DDI-DrugBank.d353.s1.p4
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
dextran
|
monoamine oxidase inhibitors
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p681
|
However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac-treated patients receiving concomitant warfarin therapy.
|
etodolac
|
warfarin
|
EFFECT
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s26
|
DDI-DrugBank.d219.s26.p0
|
Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.
|
Sympathomimetic amines
|
mecamylamine
|
EFFECT
|
Carbinoxamine_ddi.xml
|
DDI-DrugBank.d389.s2
|
DDI-DrugBank.d389.s2.p3
|
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
|
oxygen
|
furosemide
|
NONE
|
Epoprostenol_ddi.xml
|
DDI-DrugBank.d241.s3
|
DDI-DrugBank.d241.s3.p40
|
Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.
|
Indinavir
|
amprenavir
|
MECHANISM
|
Amprenavir_ddi.xml
|
DDI-DrugBank.d437.s5
|
DDI-DrugBank.d437.s5.p0
|
Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
|
carbamazepine
|
ethinyl estradiol
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s12
|
DDI-DrugBank.d485.s12.p11
|
Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.
|
Clozapine
|
benzodiazepine
|
NONE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s8
|
DDI-DrugBank.d480.s8.p3
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.